Does medication treat borderline personality disorder?

You are on three things, or five. One was started in an emergency room, one by a prescriber you saw twice, and one you cannot remember agreeing to. Each was going to help with a piece of it. Nobody has ever taken anything away.

The short answer: no medication holds a US-approved indication for borderline personality disorder, so every prescription written for the disorder itself is off-label. The Cochrane review pooled 46 randomised trials and 2,769 participants and found that "compared with placebo, no difference in effects were observed on any of the primary outcomes at the end of treatment for any medication," concluding that "no pharmacological therapy seems effective in specifically treating BPD pathology." The UK's national guideline says drug treatment "should not be used specifically for borderline personality disorder or for the individual symptoms or behaviour associated with the disorder." None of that is an argument for stopping anything on your own, and none of it applies to a depression, an anxiety disorder, ADHD or a substance use disorder that is genuinely present alongside — those get treated on their own evidence.¹ ² ³

What the evidence actually shows

The 2022 Cochrane review is the current word, and it is worth seeing by drug class. All of these are rated very low certainty, and all of them cross no effect:²

Self-harm, suicide-related outcomes and psychosocial functioning: the review describes the evidence as "very uncertain" and finds little to no effect for every class.²

The two places a signal appeared, both on a secondary outcome and both at low rather than very low certainty: antipsychotics "may slightly reduce interpersonal problems" (SMD −0.21, 8 trials, 907 participants), and mood stabilisers "may result in a reduction in this outcome" (SMD −0.58, 4 trials, 300 participants).² That is a modest and specific finding, and it is not a licence to treat the disorder pharmacologically.

Adverse events were barely studied at all. The review's words: "Reporting on adverse events was poor and mostly non-standardised," and for antidepressants, "no data on adverse events were identified."² So the benefit side is uncertain and the harm side is largely unmeasured — which is an unusual position from which to be taking five things.

The thing most articles about this get wrong

There was an earlier Cochrane review, in 2010, and it was meaningfully more positive: it reported benefits for topiramate, lamotrigine, valproate, aripiprazole and olanzapine, and concluded that "pharmacotherapy should therefore be targeted at specific symptoms."⁴

The 2022 update added 18 more trials and overturned that conclusion.² A great deal of material still online — including some clinical summaries — is repeating the 2010 version. If you read that medication should be targeted at specific BPD symptoms, check the date on what you are reading.

What the guidelines say

The UK's guideline is unusually direct, and its recommendations are worth having in front of you:³

• 1.3.5.1 "Drug treatment should not be used specifically for borderline personality disorder or for the individual symptoms or behaviour associated with the disorder (for example, repeated self-harm, marked emotional instability, risk-taking behaviour and transient psychotic symptoms)."
• 1.3.5.2 "Antipsychotic drugs should not be used for the medium- and long-term treatment of borderline personality disorder."
• 1.3.5.3 "Drug treatment may be considered in the overall treatment of comorbid conditions."
• 1.3.5.4 Short-term sedative medication in a crisis may be considered cautiously, and "the duration of treatment… should be no longer than 1 week."
• 1.3.5.6 Review the drugs of anyone with BPD and no diagnosed comorbid illness, "with the aim of reducing and stopping unnecessary drug treatment."

Australia's national guideline reaches the same place: "Medicines should not be used as primary therapy for BPD, because they have only modest and inconsistent effects, and do not change the nature and course of the disorder," alongside practice points to "use a single medicine and avoid polypharmacy, if possible," and to withdraw crisis medication once the crisis has resolved.⁵

And the US national institute's plain-language version: "Psychotherapy, or talk therapy, is the primary treatment for borderline personality disorder," and "The benefits of medication for borderline personality disorder are unclear, and it is not a first-line treatment for the disorder."⁶

What happens in practice instead

The gap between the guidance and the prescription pad is not small, and it has been counted. In a whole-country study using national dispensing data, 55.9 percent of people with BPD who were dispensed any medication were taking three or more psychotropics in 2019, up from 50 percent in 2014. Those on seven or more rose from 8.4 to 10.7 percent. Quetiapine went to 53.8 percent of medicated patients; lorazepam dispensing rose from 15.5 to 26.7 percent over five years. The authors' conclusion: "There is a large burden of psychotropic polypharmacy in people with borderline personality disorder. This is concerning because of the lack of evidence regarding the efficacy of these medications in this group."⁷

A US electronic-health-record study of 1,461 patients found antidepressants prescribed to 80.4 percent at baseline, with lamotrigine, gabapentin, quetiapine and aripiprazole the most common of the rest.⁸

This is what makes the differential with bipolar disorder consequential rather than academic: getting the label wrong in that direction is how a person ends up on a mood stabiliser and two antipsychotics for a condition that the trials say they do not treat. BPD or bipolar? →

What to do with this if you are currently taking things

Do not stop anything on your own. Several of these drugs cause withdrawal effects, some of them dangerous, and stopping abruptly in the middle of a bad month is its own risk. What this evidence justifies is a conversation, not a decision made tonight.

The conversation, in five parts:

1. Ask what each drug is being prescribed for. Not "for BPD" — for which diagnosis, and which target symptom. Write the answers down. A drug with no answer is the one to discuss.
2. Ask whether a comorbid condition is being treated. Depression, PTSD, anxiety, ADHD, bipolar disorder and substance use disorders all occur alongside BPD, and the guideline position is to treat them on their own guideline, within the structured treatment for BPD.³ That is legitimate prescribing.
3. Ask about the plan for reduction, if there is no diagnosed comorbid illness — which is what recommendation 1.3.5.6 asks prescribers to do.³
4. Ask about anything started in a crisis. Crisis prescribing is meant to be short — the UK guideline says no longer than a week for sedatives — and it is the category most likely to have been left running for two years.³ ⁵
5. Ask what the psychotherapy plan is. If there isn't one, that is the actual gap. Structured psychotherapy is the treatment with the evidence. What a full DBT programme includes →

Bring a written list of everything you take, with doses and start dates, and ask for the answers in writing. Requesting your records →

Q&A

Q: Is there an FDA-approved medication for borderline personality disorder? A: No. A search of US drug labelling finds no product listing BPD in its Indications and Usage section, which means all prescribing for the disorder itself is off-label.¹ Off-label prescribing is legal and common; it just means the evidence has to come from somewhere other than an approval.

Q: So medication is useless? A: No — it is not established as effective for BPD itself. It can be entirely appropriate for a co-occurring condition, and short-term use in a crisis is contemplated by the guidelines with limits attached.³ ⁵ The problem the data describe is accumulation without review.

Q: What about omega-3? A: Three small trials, and the results are inconsistent: in one trial of 49 participants there was a signal on suicide-related outcomes and on depression, and across two small trials a signal on anger, while self-harm showed no clear difference.² These are single small studies without a certainty rating attached, and worth mentioning to a prescriber rather than treating as an established treatment.

Q: My psychiatrist wants to add something. Should I refuse? A: Not on the strength of a web page. Ask which diagnosis it treats, what the target is, when it will be reviewed, and what would count as it not working. Those four questions are reasonable and answerable, and the answers will tell you a lot.

Q: I feel better on my medication. Doesn't that mean it works? A: It might — for a comorbid condition, or for sleep, or through effects the trials do not capture well. What the pooled trials say is that at group level, medication did not separate from placebo on BPD's core outcomes. Your own response is worth taking seriously and worth reviewing periodically with someone who knows what you are treating.

Q: What about medication for a teenager with BPD? A: The evidence base is thinner still: the Cochrane review notes that only one included trial had a mean age below 18, and that "these results may not be applicable for adolescent populations."² Diagnosing BPD before 18 →

Ready to get the psychotherapy half in place? Filter therapists by approach, schedule and payment route → · The full BPD map → · Check a DBT programme →

Sources

1. US Food and Drug Administration, structured product labelling database (openFDA), searched September 2026 — no US drug label lists borderline personality disorder in its Indications and Usage section — open.fda.gov; the Cochrane review states the same in its background: "medication use is off-label as a treatment for BPD."
2. Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J, et al., "Pharmacological interventions for people with borderline personality disorder," Cochrane Database of Systematic Reviews 11, 2022, CD012956 — 46 trials, 2,769 participants, 29 medications; "Compared with placebo, no difference in effects were observed on any of the primary outcomes at the end of treatment for any medication"; class-by-class effect sizes; "Low-certainty evidence suggests that antipsychotics may slightly reduce interpersonal problems (SMD -0.21…)"; "Reporting on adverse events was poor and mostly non-standardised"; "The review supports the continued understanding that no pharmacological therapy seems effective in specifically treating BPD pathology"; the omega-3 analyses; and the note that results "may not be applicable for adolescent populations" — pmc.ncbi.nlm.nih.gov.
3. National Institute for Health and Care Excellence, "Borderline personality disorder: recognition and management," clinical guideline CG78, section 1.3.5 and recommendation 1.3.6.2 — nice.org.uk.
4. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM, "Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials," British Journal of Psychiatry 196(1), 2010, 4–12 — the earlier, more positive conclusion that "pharmacotherapy should therefore be targeted at specific symptoms," superseded by the 2022 update — doi.org.
5. National Health and Medical Research Council, "Clinical practice guideline for the management of borderline personality disorder," Melbourne, 2012 — recommendation 11, "Medicines should not be used as primary therapy for BPD, because they have only modest and inconsistent effects, and do not change the nature and course of the disorder"; recommendations 12 to 17 and 20 on time-limited adjunctive use, caution with medicines lethal in overdose or associated with dependence, avoiding polypharmacy, and withdrawing crisis medication once the crisis resolves — nhmrc.gov.au.
6. National Institute of Mental Health, "Borderline Personality Disorder" — "Psychotherapy, or talk therapy, is the primary treatment for borderline personality disorder"; "The benefits of medication for borderline personality disorder are unclear, and it is not a first-line treatment for the disorder" — nimh.nih.gov.
7. Tennant M, Frampton C, Mulder R, Beaglehole B, "Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases," BJPsych Open 9(6), 2023, e200 — "Fifty percent of people with borderline personality disorder who were dispensed medications had three or more psychotropic medications in 2014. This increased to 55.9% in 2019… Those on seven or more psychotropics increased from 8.4 to 10.7%… Quetiapine was the most dispensed psychotropic medication, being given to 53.8% of people dispensed medication with borderline personality disorder in 2019. Lorazepam dispensing showed the largest increase, going from 15.5 to 26.7%" — pmc.ncbi.nlm.nih.gov.
8. White C, St Rose S, Dwyer JB, et al., "Treatment trajectories of patients with borderline personality disorder prescribed pharmacotherapy: real-world insights from a retrospective observational study," BMC Psychiatry 26, 2026, 351 — antidepressants prescribed to 80.4% at baseline; lamotrigine 24.9%, gabapentin 15.4%, quetiapine 22.1%, aripiprazole 19.0% — pubmed.ncbi.nlm.nih.gov.

Paid for by participating therapists. Inclusion is computed from availability data — never purchased. No ads, no data sold.